Posted by Michael Wonder on 20 Feb 2021
Pfizer and BioNTech submit COVID-19 vaccine stability data at standard freezer temperature to the U.S. FDA
19 February 2021 - Pfizer and BioNTech today announced the submission of new data to the U.S. FDA demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators.
The data have been submitted to the FDA to support a proposed update to the U.S. Emergency Use Authorisation prescribing Information, which would allow for vaccine vials to be stored at these temperatures for a total of two weeks as an alternative or complement to storage in an ultra-low temperature freezer.
